Sponsor or institution

Clinical trials and research at The First Affiliated Hospital of Nanchang University

• 11Clinical trials
• 1Country

Newest trials

All recruiting trials (11)

• CG-105-12 treatment for relapsed or refractory multiple myeloma

  This study will test a single infusion of CG-105-12, an autologous BCMA-targeted CAR‑T therapy, in adults with BCMA-positive relapsed or refractory multiple myeloma who have had at least three prior treatments.

  Recruiting Early Phase 1 The First Affiliated Hospital of Nanchang University · Nanchang, Jiangxi · NCT06999031

• Personalized treatment for advanced lung cancer using a vaccine, PD-1 inhibitor, and radiotherapy

  This study is testing a new personalized treatment for advanced lung cancer that combines a vaccine, a PD-1 inhibitor, and radiotherapy to see if it helps patients whose cancer has progressed after initial therapy.

  Recruiting at 2 sites The First Affiliated Hospital of Nanchang University · Nanchang, Jiangxi and 1 other locations · NCT06752057

• Personalized treatment combining a peptide vaccine, PD-1 inhibitor, and radiotherapy for advanced lung cancer

  This study is testing a new treatment for advanced lung cancer that combines a personalized vaccine, a PD-1 inhibitor, and radiotherapy to see if it helps patients who haven't responded to other therapies.

  Recruiting at 2 sites The First Affiliated Hospital of Nanchang University · Nanchang, Jiangxi and 1 other locations · NCT06752044

• Personalized vaccine combined with third-line therapy for advanced colorectal cancer

  This study is testing if a personalized vaccine, along with standard treatment, can help people with advanced colorectal cancer who haven't responded to previous therapies.

  Recruiting at 2 sites The First Affiliated Hospital of Nanchang University · Nanchang, Jiangxi and 1 other locations · NCT06751966

• Personalized vaccine and therapy for advanced colorectal cancer

  This study is testing a personalized vaccine combined with standard treatment for people with advanced colorectal cancer who haven't improved after previous therapies.

  Recruiting at 2 sites The First Affiliated Hospital of Nanchang University · Nanchang, Jiangxi and 1 other locations · NCT06751953

• Personalized vaccine and second-line therapy for advanced colorectal cancer

  This study is testing a personalized vaccine combined with standard therapy to see if it helps people with advanced colorectal cancer who haven't responded to their first treatment.

  Recruiting at 2 sites The First Affiliated Hospital of Nanchang University · Nanchang, Jiangxi and 1 other locations · NCT06751940

• Personalized peptide vaccine combined with second-line therapy for advanced colorectal cancer

  This study is testing a personalized vaccine combined with standard treatment to see if it helps people with advanced colorectal cancer who haven't responded to their first treatment.

  Recruiting at 2 sites The First Affiliated Hospital of Nanchang University · Nanchang, Jiangxi and 1 other locations · NCT06751914

• Personalized vaccine and PD-1 inhibitor with radiotherapy for advanced lung cancer

  This study is testing a new treatment combining a personalized vaccine, a PD-1 inhibitor, and radiotherapy to see if it can help people with advanced lung cancer who haven't responded to previous therapies.

  Recruiting at 2 sites Phase 2 The First Affiliated Hospital of Nanchang University · Nanchang, Jiangxi and 1 other locations · NCT06751901

• Personalized treatment combining a DC vaccine, PD-1 inhibitor, and radiotherapy for advanced lung cancer

  This study is testing a new personalized treatment for advanced lung cancer that combines a special vaccine, a PD-1 blocker, and radiation to see if it helps patients whose cancer has not improved with previous therapies.

  Recruiting at 2 sites Phase 2 The First Affiliated Hospital of Nanchang University · Nanchang, Jiangxi and 1 other locations · NCT06751849

• Orelabrutinib plus rituximab versus R‑CVP as first-line treatment for marginal zone lymphoma

  This test will see if orelabrutinib plus rituximab, followed by orelabrutinib maintenance, works as well or better than standard R‑CVP chemotherapy for adults with untreated marginal zone lymphoma.

  Recruiting Phase 2 The First Affiliated Hospital of Nanchang University · Nanchang, Jiangxi · NCT06700798

• Personalized neoantigen vaccine treatment for advanced solid tumors

  This study is testing a personalized vaccine treatment for people with advanced solid tumors to see if it can help their immune system fight the cancer better.

  Recruiting The First Affiliated Hospital of Nanchang University · Nanchang, Jiangxi · NCT05749627

Quick answers

How many clinical trials run by The First Affiliated Hospital of Nanchang University are recruiting right now?

11, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →